Development of new positive electrode materials for rechargeable zinc-ion intercalation batteries to overcome energy capacity and stability limitations
开发用于可充电锌离子嵌入电池的新型正极材料,以克服能量容量和稳定性限制
基本信息
- 批准号:556905-2020
- 负责人:
- 金额:$ 4.9万
- 依托单位:
- 依托单位国家:加拿大
- 项目类别:Alliance Grants
- 财政年份:2022
- 资助国家:加拿大
- 起止时间:2022-01-01 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Three McMaster-based investigators will collaborate with Salient Energy to discover, develop and implement new, high performance positive electrode materials for rechargeable zinc-ion intercalation batteries (Zn-ion batteries). This project will directly address the energy storage capacity, capacity retention and cost limitations of current state-of-the-art manganese oxide electrodes that limit their techno-economic viability for energy storage applications. Particularly, Zn-ion batteries are targeted for non-portable applications, such as grid-scale energy storage - a sector predicted to grow to >$15 billion annually by 2030. High performance and affordable batteries are needed for these applications, as they will enable carbon emissions reductions by providing load leveling/storage to facilitate the integration of renewable but variable energy source (wind, solar) into global electricity infrastructures. The interdisciplinary project team will take a targeted and holistic approach to discover, understand and implement new positive electrode materials for rechargeable Zn-ion batteries to address performance, stability and cost challenges. The approach includes: (1) Experimental synthesis, characterization and integration of newly designed positive electrode materials into Zn-ion batteries for performance evaluation; (2) Computational materials discovery, where hundreds of compounds will be screened based on first principles and down selected to guide experimental activities; and (3) in situ characterization of existing and new positive electrode Zn-ion battery materials to understand mechanisms and guide computational/experimental efforts. This project will result in Zn-ion battery materials and technology designs with higher performance and decreased cost. These inventions will be transferred to Salient Energy for pilot-scale production and demonstration, with the intellectual property expected to provide Canada a competitive edge in the manufacture and sale of rechargeable Zn-ion batteries for grid scale energy storage.
三名麦克马斯特大学的研究人员将与Salient Energy合作,发现、开发和实施用于可充电锌离子插入电池(锌离子电池)的新型高性能正极材料。该项目将直接解决当前最先进的氧化锰电极的储能容量、容量保持和成本限制,这些限制了它们在储能应用中的技术经济可行性。特别是,锌离子电池的目标是非便携式应用,比如电网规模的能源存储——到2030年,这一领域预计将增长到每年150亿美元。这些应用需要高性能和价格合理的电池,因为它们将通过提供负载均衡/存储来减少碳排放,从而促进可再生但可变的能源(风能、太阳能)与全球电力基础设施的整合。跨学科项目团队将采取有针对性和全面的方法来发现、理解和实施可充电锌离子电池的新正极材料,以解决性能、稳定性和成本方面的挑战。该方法包括:(1)实验合成、表征并将新设计的正极材料集成到锌离子电池中进行性能评估;(2)计算材料发现,数百种化合物将根据第一性原理进行筛选,并从中选出来指导实验活动;(3)原位表征现有和新的正极锌离子电池材料,以了解机制和指导计算/实验工作。该项目将带来性能更高、成本更低的锌离子电池材料和工艺设计。这些发明将被转移到Salient Energy进行中试规模的生产和示范,其知识产权有望为加拿大在制造和销售用于电网规模储能的可充电锌离子电池方面提供竞争优势。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Higgins, DrewDC其他文献
Higgins, DrewDC的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Higgins, DrewDC', 18)}}的其他基金
Converting Biomass Waste into Energy Storage Materials
将生物质废物转化为储能材料
- 批准号:
580587-2022 - 财政年份:2022
- 资助金额:
$ 4.9万 - 项目类别:
Alliance Grants
相似国自然基金
脊髓新鉴定SNAPR神经元相关环路介导SCS电刺激抑制恶性瘙痒
- 批准号:82371478
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
tau轻子衰变与新物理模型唯象研究
- 批准号:11005033
- 批准年份:2010
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
HIV gp41的NHR区新靶点的确证及高效干预
- 批准号:81072676
- 批准年份:2010
- 资助金额:33.0 万元
- 项目类别:面上项目
强子对撞机上新物理信号的多轻子末态研究
- 批准号:10675110
- 批准年份:2006
- 资助金额:36.0 万元
- 项目类别:面上项目
相似海外基金
Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.
开发化合物 RUEC2-118,这是一种新型部分 GABAAR 正调节剂,可快速治疗一般性焦虑和恐慌症,以预防阿片类药物和苯二氮卓类药物过量死亡。
- 批准号:
10684503 - 财政年份:2023
- 资助金额:
$ 4.9万 - 项目类别:
Uncover mechanisms underlying the development of chronic lung sequelae post COVID-19
揭示 COVID-19 后慢性肺部后遗症发生的机制
- 批准号:
10734747 - 财政年份:2023
- 资助金额:
$ 4.9万 - 项目类别:
Development of first-in-class antagonists of the retinoid pathway as novel oral immunotherapies for solid cancers
开发类视黄醇途径的一流拮抗剂作为实体癌的新型口服免疫疗法
- 批准号:
10604218 - 财政年份:2023
- 资助金额:
$ 4.9万 - 项目类别:
Investigational new drug enabling studies for the development of a topical fixed dose combination drug product to treat actinic keratosis and prevent cutaneous squamous cell carcinoma.
研究性新药使研究能够开发局部固定剂量组合药物产品,以治疗光化性角化病和预防皮肤鳞状细胞癌。
- 批准号:
10482509 - 财政年份:2022
- 资助金额:
$ 4.9万 - 项目类别:
Preclinical and early clinical development of a GABA-A a5 PAM
GABA-A a5 PAM 的临床前和早期临床开发
- 批准号:
10686404 - 财政年份:2022
- 资助金额:
$ 4.9万 - 项目类别:
Development of a Therapeutic SAPNANO-ESO Vaccine for Prostate Cancer
开发治疗前列腺癌的 SAPNANO-ESO 疫苗
- 批准号:
10546765 - 财政年份:2022
- 资助金额:
$ 4.9万 - 项目类别:
MiR-152/PKM2/SLC7A5 axis in breast cancer development, chemo- and radiation-treatment response
MiR-152/PKM2/SLC7A5 轴在乳腺癌发展、化疗和放疗反应中的作用
- 批准号:
10593136 - 财政年份:2022
- 资助金额:
$ 4.9万 - 项目类别:
Development of resident memory T cells in the synovium
滑膜中常驻记忆 T 细胞的发育
- 批准号:
10427963 - 财政年份:2022
- 资助金额:
$ 4.9万 - 项目类别:
Preclinical and early clinical development of a GABA-A a5 PAM
GABA-A a5 PAM 的临床前和早期临床开发
- 批准号:
10810466 - 财政年份:2022
- 资助金额:
$ 4.9万 - 项目类别:
Investigational new drug enabling studies for the development of a topical fixed dose combination drug product to treat actinic keratosis and prevent cutaneous squamous cell carcinoma.
研究性新药使研究能够开发局部固定剂量组合药物产品,以治疗光化性角化病和预防皮肤鳞状细胞癌。
- 批准号:
10701001 - 财政年份:2022
- 资助金额:
$ 4.9万 - 项目类别: